Real-World Use and Effectiveness of Internet-Based Vestibular Rehabilitation Following Nationwide Implementation: Prospective Observational Cohort Study
JMIR Rehabilitation and Assistive Technologies · 20.11.2026 · 13 · e106458
DOI: 10.2196/106458 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JMIR Rehabilitation and Assistive Technologies, online erschienen am 20.11.2026. Verfasst von Hà TN Ngo und 4 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Vestibular rehabilitation is a safe and effective exercise-based treatment for various vestibular disorders, yet it is underused by general practitioners. Following a randomized controlled trial demonstrating the effectiveness of Vertigo Training, an internet-based vestibular rehabilitation program, a nationwide implementation was initiated in the Netherlands.
Objective
This study aimed to evaluate the real-world use and effectiveness of Vertigo Training on vestibular symptoms.
Methods
We conducted a prospective observational cohort study by using anonymized data from Vertigo Training users (period 2023-2025). Individuals were eligible if they reported vestibular symptoms for at least 1 month, irrespective of the underlying cause. Main analyses focused on users who completed voluntary questionnaires, capturing demographic and clinical characteristics. We evaluated the effectiveness using the Vertigo Symptom Scale—Short Form (VSS-SF). Factors associated with treatment success (defined as ≥3-point reduction in VSS-SF score at 3 months) were analyzed using multivariable logistic regression. To contextualize these outcomes, we used program-level data and additional voluntary questionnaires to describe engagement and adherence.
Results
A total of 2156 users were included for the main analyses (median age 60, IQR 48-70 years; n=1427, 66% women). The most frequently self-reported diagnoses were benign paroxysmal positional vertigo and vestibular neuritis. Median VSS-SF scores improved from 17 (IQR 12-22) at baseline to 11 (IQR 6-18) at 3 months, with 63% (155/247) achieving treatment success. Higher baseline VSS-SF scores were associated with a greater likelihood of treatment success (odds ratio 1.1, 95% CI 1.0-1.1), as was a diagnosis of benign paroxysmal positional vertigo (risk ratio 1.7, 95% CI 1.1-2.0). These outcomes were observed in a context where engagement declined over time, with 43% (1442/3367) of users progressing to week 2, and adherence to the recommended exercise frequency averaged 13%.
Conclusions
In this real-world cohort, Vertigo Training was associated with meaningful reductions in vestibular symptoms following nationwide implementation. These findings confirm its effectiveness beyond the trial setting and support broader integration of internet-based vestibular rehabilitation into routine care. However, sustained engagement remains an important target for future research and optimization. International Registered Report Identifier (IRRID) RR2-10.1186/s43058-023-00524-1
Zitieren
APA
Ngo, H. T., Maarsingh, O. R., Blanker, M. H., Bont, J., & Vugt, V. A. V. (2026). Real-World Use and Effectiveness of Internet-Based Vestibular Rehabilitation Following Nationwide Implementation: Prospective Observational Cohort Study. JMIR Rehabilitation and Assistive Technologies, 13, e106458. https://doi.org/10.2196/106458
Vancouver
Ngo HT, Maarsingh OR, Blanker MH, Bont J, Vugt VAV. Real-World Use and Effectiveness of Internet-Based Vestibular Rehabilitation Following Nationwide Implementation: Prospective Observational Cohort Study. JMIR Rehabilitation and Assistive Technologies. 2026;13:e106458. doi:10.2196/106458
BibTeX
@article{Ngo2026,
author = {Ngo, Hà TN and Maarsingh, Otto R and Blanker, Marco H and Bont, Jettie and Vugt, Vincent A van},
title = {Real-World Use and Effectiveness of Internet-Based Vestibular Rehabilitation Following Nationwide Implementation: Prospective Observational Cohort Study},
journal = {JMIR Rehabilitation and Assistive Technologies},
year = {2026},
volume = {13},
pages = {e106458},
doi = {10.2196/106458}
}
EUVIMED